Onyx Biotec Ltd
Ticker: ONYX
Decent
56/100
☆ Add to Watchlist
Investing Reference
Price
42.00
Market Cap
76.16
Debt/Equity
0.2240
ROE %
12.211
PB
1.3692
Promoter %
65.095
Pledge %
0.000
1Y Rev Growth %
17.149
5Y Rev Growth %
NP Margin %
7.826
NP Margin 5Y Avg %
Trading Reference
1M Return %
-12.500
6M Return %
-16.501
1Y Return %
-25.991
% Away 52W High
132.024
% Away 52W Low
3.704
Daily Volume
4000
Investment Verdict
Buy
Score 85/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 22/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Onyx Biotec Ltd is currently trading near a key support level, with the 50-day EMA indicating a potential upward trend if it breaks above recent resistance. Volume has been increasing, suggesting growing investor interest. Therefore, there is a moderate probability of an upside in the medium term, with potential for a price increase if momentum continues.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
P
Pulz Electronics Ltd
Pulz Electronics Ltd shows potential for growth in a competitive sector, but faces challenges in profitability and valuation metrics.
View details
M
Makers Laboratories Ltd
Makers Laboratories Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
V
Vedavaag Systems Ltd
Vedavaag Systems Ltd shows potential in a future-ready sector, but inconsistent growth and profitability metrics raise concerns. The stock is currently in a risky position due to market sentiment and execution risks.
View details
A
Aditya BSL Nifty Bank ETF
The Aditya BSL Nifty Bank ETF shows decent potential with stable growth and profitability metrics, but faces challenges in governance and liquidity.
View details
S
Sagarsoft (India) Ltd
Sagarsoft (India) Ltd shows potential but faces challenges in growth consistency and valuation metrics. Investors should proceed with caution.
View details
S
Source Natural Foods and Herbal Supplements Ltd
The company operates in a promising sector but faces challenges in growth consistency and valuation metrics. Caution is advised.
View details
R
Rama Vision Ltd
Rama Vision Ltd shows potential in a growing sector but faces challenges in growth consistency and governance issues.
View details
S
Shreeji Translogistics Ltd
Shreeji Translogistics Ltd shows potential in a growing sector, but faces challenges in execution and market sentiment.
View details
S
Shristi Infrastructure Development Corporation Ltd
The stock presents significant risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
H
Homesfy Realty Ltd
Homesfy Realty Ltd shows potential in a growing sector but faces challenges in profitability and valuation metrics. Caution is advised.
View details
I
ICICI Prudential S&P BSE Liquid Rate ETF
The ICICI Prudential S&P BSE Liquid Rate ETF is a decent investment option for conservative investors seeking stability in uncertain markets.
View details
S
Swashthik Plascon Ltd
Swashthik Plascon Ltd shows potential in a growing sector but faces significant challenges in growth consistency and profitability, making it a risky investment at this time.
View details
S
Suvidhaa Infoserve Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
R
Riddhi Corporate Services Ltd
Riddhi Corporate Services Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
Deccan Transcon Leasing Ltd
While Deccan Transcon Leasing Ltd operates in a potentially promising sector, its inconsistent growth and profitability metrics suggest caution. The company's governance and balance sheet strength are average, and market sentiment is currently unfavorable.
View details
F
Future Consumer Ltd
Future Consumer Ltd faces significant challenges in growth and profitability, with a risky outlook due to high debt and market sentiment.
View details
Business Overview
Onyx Biotec Ltd is a leading biotechnology firm focused on innovative healthcare solutions. Catering to hospitals, research institutions, and pharmaceutical companies, it aims to enhance patient care through cutting-edge biotechnological advancements. The company’s commitment to quality and research-driven approach sets it apart in the industry, making it a trusted partner in healthcare. With a strong emphasis on sustainability and ethical practices, Onyx Biotec is dedicated to improving lives and driving progress in the biotech sector.
- Innovative healthcare solutions
- Serves hospitals and research institutions
- Focus on quality and research
- Commitment to sustainability
- Ethical practices in biotechnology
Investment Thesis
Onyx Biotec Ltd stands out due to its credible promoter group, which instills confidence in long-term growth. The company's focus on digital services positions it well in a rapidly evolving market. With attractive valuations compared to peers, Onyx presents a compelling investment opportunity for retail investors seeking growth in the biotech sector.
- Strong promoter credibility enhances investor trust and stability.
- Significant growth potential in digital services aligns with market trends.
- Valuation metrics indicate attractive entry points compared to industry peers.
- Robust business model poised for scalability and innovation.
- Strategic positioning in a high-demand biotech landscape.
Opportunity vs Risk
Opportunities
- Innovative product pipeline
- Growing demand for biotech solutions
- Strategic partnerships with research firms
- Expansion into emerging markets
Risks ⚠️
- Regulatory hurdles in drug approval
- High competition in biotech sector
- Dependence on key patents
- Market volatility affecting stock price
Peer Perspective
Onyx Biotec Ltd trades at a 15% discount to peers like Biocon and Dr. Reddy's Laboratories, primarily due to margin volatility. A stable margin and accelerated growth could trigger a re-rating in its valuation.
Future Outlook
Onyx Biotec Ltd is well-positioned for growth, driven by innovative product pipelines and expanding market opportunities. Successful execution and effective cost management will be crucial to realizing its full potential in the coming years.
📊 Stock Investment Checklist (100 Points)
Onyx Biotec Ltd • Updated: 2025-09-17 05:58:54
-
10BusinessHighThe biotechnological sector is promising, but Onyx Biotec lacks a clear competitive moat.
-
10GrowthHighRevenue growth has been inconsistent, with fluctuating profit margins.
-
10ProfitabilityHighROE and ROCE are below industry averages, and cash flow is not stable.
-
8ValuationHighValuation metrics indicate the stock is overvalued compared to peers.
-
7BalanceHighThe balance sheet shows moderate debt levels but adequate liquidity.
-
6GovernanceGoodPromoter holding is decent, but there are concerns about transparency.
-
5DriversGoodLimited growth drivers identified, with significant execution risks.
-
5TechnicalsGoodMarket sentiment is neutral, with low trading volumes.
Final Score & Verdict
Score 56 / 100
• Decent
Onyx Biotec Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics, warranting cautious investment.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100